Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer

The anti-programmed cell death-1 (PD-1) antibody nivolumab has been shown to significantly prolong the survival of patients with unresectable advanced or recurrent gastric cancer (AGC). However, immune-related adverse events (irAEs), which show different profiles from those of cytotoxic agents or co...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-10, Vol.13
Main Authors: Ohmura, Hirofumi, Kondo, Moe, Uenomachi, Masato, Ariyama, Hiroshi, Ito, Mamoru, Tsuchihashi, Kenji, Ayano, Masahiro, Niiro, Hiroaki, Akashi, Koichi, Baba, Eishi
Format: Article
Language:English
Subjects:
gastric cancer
irAE
nivolumab
Oncology
pathology
RS3PE
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The anti-programmed cell death-1 (PD-1) antibody nivolumab has been shown to significantly prolong the survival of patients with unresectable advanced or recurrent gastric cancer (AGC). However, immune-related adverse events (irAEs), which show different profiles from those of cytotoxic agents or conventional molecular-targeted drugs including tyrosine kinase inhibitors, have been reported. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is a rare autoimmune disorder with acute-onset, rheumatoid factor-negative, symmetric synovitis associated with limb edema observed in elderly persons. A case of RS3PE syndrome that developed after administration of nivolumab for advanced gastric cancer is reported. This is the first report of a case of RS3PE syndrome as an irAE caused by nivolumab in a patient with gastric cancer.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1260818